表紙
市場調查報告書
商品編碼
1019948

乾眼症:Market Spotlight

Market Spotlight: Dry Eye Disease

出版日期: | 出版商: Datamonitor Healthcare | 英文 62 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球乾眼症的患病人數,2020年估計為15億2,000萬人,預計2029年患病人數增加到17億2,000萬人。在乾眼症的領域認證的醫藥品,以多樣的目標為焦點。認證藥物的大部分是局部施藥,不過,也存在眼內/視網膜下/結膜下製劑可以使用的產品。進行乾眼症活躍的臨床開發,大半為第二階段,NDA/BLA的階段只有1件。

本報告提供乾眼症的相關調查,疾病背景,治療,流行病學,醫藥品和開發平台藥物,臨床試驗情勢,商機等資訊。

目錄

內容

概要

要點

疾病的背景

  • 定義
  • 患者的市場區隔
  • 症狀
  • 危險因素
  • 診斷

治療

  • 眼的潤滑劑
  • 處方藥
  • 眼皮的衛生
  • 外科的治療

流行病學

醫藥品

開發平台藥物

最近的事件和分析師的意見

  • 乾眼症用NovaTears(2021年4月13日)
  • 乾眼症用RGN-259(2021年3月18日)
  • 乾眼症用Visomitin(2021年2月22日)
  • 乾眼症用Reproxalap(2021年1月7日)
  • 乾眼症用NovaTears(2020年12月22日)
  • 乾眼症用PL-9643(2020年12月15日)
  • 乾眼症用Voclosporin眼藥水(VOS)(2020年11月2日)
  • 乾眼症用OC-01滴鼻劑(2020年5月11日)
  • 乾眼症用EYSUVIS(2020年3月9日)
  • 乾眼症用Reproxalap(2019年12月3日)
  • 乾眼症用OC-01滴鼻劑(2019年10月4日)

今後主要的活動

主要的法規活動

  • Oyster Point Pharma提交OC-01滴鼻劑的NDA
  • FDA核准乾眼症疾病用Eysuvis
  • EMA不相信Xiidra的乾眼症相關資料

成功的概率

授權及資產取得的交易

  • IACTA供給Zhaoke乾眼症及結膜炎治療藥的許可證

商機

臨床試驗情勢

  • 各狀態的贊助商
  • 各階段的贊助商
  • 最近的活動

參考文件

附錄

圖的清單

表格的清單

目錄
Product Code: DMKC0206778

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2020, there were 1.52 billion prevalent cases of dry eye worldwide, and forecasts that number to increase to 1.72 billion prevalent cases by 2029.

The approved drugs in the dry eye space focus on a wide variety of targets. The majority of approved drugs are administered via the topical route, with one product available as an intraocular/subretinal/subconjunctival formulation.

The majority of industry-sponsored drugs in active clinical development for dry eye are in Phase II, with only one drug in the NDA/BLA phase.

Therapies in development for dry eye focus on a wide variety of targets. The majority of pipeline drugs are administered via the topical route, with the remainder being intranasal, oral, and intraocular/subretinal/subconjunctival formulations.

High-impact upcoming events for drugs in the dry eye space comprise topline Phase II trial results for NRO-1, ECF843, and OTXCSI; topline Phase IIb trial results for AR-15512; topline Phase III trial results for MIM-D3 and CyclASol; and an expected PDUFA date for OC-01 Nasal Spray.

The overall likelihood of approval of a Phase I ophthalmology-other asset is 22.8%, and the average probability a drug advances from Phase III is 55%. Drugs, on average, take 8.6 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for dry eye have been in the late phases of development, with 56% of trials in Phase III-IV, and only 44% in Phase I-II.

The US has a substantial lead in the number of dry eye clinical trials globally. France leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the dry eye space is dominated by completed trials. Novartis has the highest number of completed clinical trials for dry eye, with 87 trials.

Novartis leads industry sponsors with the highest overall number of clinical trials for dry eye, followed by AbbVie.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Ocular lubricants
  • Prescription drugs
  • Eyelid hygiene
  • Surgical treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • NovaTears for Dry Eye (April 13, 2021)
  • RGN-259 for Dry Eye (March 18, 2021)
  • Visomitin for Dry Eye (February 22, 2021)
  • Reproxalap for Dry Eye (January 7, 2021)
  • NovaTears for Dry Eye (December 22, 2020)
  • PL-9643 for Dry Eye (December 15, 2020)
  • Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020)
  • OC-01 Nasal Spray for Dry Eye (May 11, 2020)
  • EYSUVIS for Dry Eye (March 9, 2020)
  • Reproxalap for Dry Eye (December 3, 2019)
  • OC-01 Nasal Spray for Dry Eye (October 4, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Oyster Point Pharma Submits NDA For OC-01 Nasal Spray
  • FDA Approves Eysuvis For Dry Eye Disease
  • EMA Unconvinced By Xiidra Dry Eye Data

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • IACTA Licenses Dry Eye, Conjunctivitis Candidates To Zhaoke

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of dry eye disease, 2020-29
  • Figure 2: Overview of pipeline drugs for dry eye disease in the US
  • Figure 3: Pipeline drugs for dry eye disease, by company
  • Figure 4: Pipeline drugs for dry eye disease, by drug type
  • Figure 5: Pipeline drugs for dry eye disease, by classification
  • Figure 6: NovaTears for Dry Eye (April 13, 2021): Phase III - GOBI
  • Figure 7: RGN-259 for Dry Eye (March 18, 2021): Phase III - ARISE-3 (US)
  • Figure 8: Visomitin for Dry Eye (February 22, 2021): Phase III - VISTA-2
  • Figure 9: Reproxalap for Dry Eye (January 7, 2021): Phase III - TRANQUILITY
  • Figure 10: NovaTears for Dry Eye (December 22, 2020): Phase II - SEECASE
  • Figure 11: PL-9643 for Dry Eye (December 15, 2020): Phase II - PL9643-201
  • Figure 12: Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020): Phase II/III - AUDREY
  • Figure 13: OC-01 Nasal Spray for Dry Eye (May 11, 2020): Phase III - ONSET-2
  • Figure 14: EYSUVIS for Dry Eye (March 9, 2020): Phase III - STRIDE 3
  • Figure 15: Reproxalap for Dry Eye (December 3, 2019): Phase III - RENEW
  • Figure 16: OC-01 Nasal Spray for Dry Eye (October 4, 2019): Phase IIb - ONSET-1
  • Figure 17: Key upcoming events in dry eye disease
  • Figure 18: Probability of success in the ophthalmology-other pipeline
  • Figure 19: Clinical trials in dry eye disease
  • Figure 20: Top 10 drugs for clinical trials in dry eye disease
  • Figure 21: Top 10 companies for clinical trials in dry eye disease
  • Figure 22: Trial locations in dry eye disease
  • Figure 23: Dry eye disease trials status
  • Figure 24: Dry eye disease trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of dry eye disease, 2020-29
  • Table 2: Marketed drugs for dry eye disease
  • Table 3: Pipeline drugs for dry eye disease in the US
  • Table 4: NovaTears for Dry Eye (April 13, 2021)
  • Table 5: RGN-259 for Dry Eye (March 18, 2021)
  • Table 6: Visomitin for Dry Eye (February 22, 2021)
  • Table 7: Reproxalap for Dry Eye (January 7, 2021)
  • Table 8: NovaTears for Dry Eye (December 22, 2020)
  • Table 9: PL-9643 for Dry Eye (December 15, 2020)
  • Table 10: Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020)
  • Table 11: OC-01 Nasal Spray for Dry Eye (May 11, 2020)
  • Table 12: EYSUVIS for Dry Eye (March 9, 2020)
  • Table 13: Reproxalap for Dry Eye (December 3, 2019)
  • Table 14: OC-01 Nasal Spray for Dry Eye (October 4, 2019)
  • Table 15: Historical global sales, by drug ($m), 2016-20
  • Table 16: Forecasted global sales, by drug ($m), 2021-25